174 related articles for article (PubMed ID: 37788110)
1. A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a in mice with G6PC c.648G>T.
Ito K; Tajima G; Kamisato C; Tsumura M; Iwamoto M; Sekiguchi Y; Numata Y; Watanabe K; Yabe Y; Kanki S; Fujieda Y; Goto K; Sogawa Y; Oitate M; Nagase H; Tsuji S; Nishizawa T; Kakuta M; Masuda T; Onishi Y; Koizumi M; Nakamura H; Okada S; Matsuo M; Takaishi K
J Clin Invest; 2023 Dec; 133(23):. PubMed ID: 37788110
[TBL] [Abstract][Full Text] [Related]
2. Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice.
Clar J; Mutel E; Gri B; Creneguy A; Stefanutti A; Gaillard S; Ferry N; Beuf O; Mithieux G; Nguyen TH; Rajas F
Hum Mol Genet; 2015 Apr; 24(8):2287-96. PubMed ID: 25561689
[TBL] [Abstract][Full Text] [Related]
3. A glycogen storage disease type 1a patient with type 2 diabetes.
Sun Y; Qiang W; Wu R; Yin T; Yuan J; Yuan J; Gu Y
BMC Med Genomics; 2022 Sep; 15(1):205. PubMed ID: 36167523
[TBL] [Abstract][Full Text] [Related]
4. G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a.
Roseman DS; Khan T; Rajas F; Jun LS; Asrani KH; Isaacs C; Farelli JD; Subramanian RR
Mol Ther; 2018 Mar; 26(3):814-821. PubMed ID: 29428299
[TBL] [Abstract][Full Text] [Related]
5. Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.
Arnaoutova I; Zhang L; Chen HD; Mansfield BC; Chou JY
Mol Ther; 2021 Apr; 29(4):1602-1610. PubMed ID: 33359667
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.
Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY
Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177
[TBL] [Abstract][Full Text] [Related]
7. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
[TBL] [Abstract][Full Text] [Related]
8. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
[TBL] [Abstract][Full Text] [Related]
9. Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas.
Mutel E; Abdul-Wahed A; Ramamonjisoa N; Stefanutti A; Houberdon I; Cavassila S; Pilleul F; Beuf O; Gautier-Stein A; Penhoat A; Mithieux G; Rajas F
J Hepatol; 2011 Mar; 54(3):529-37. PubMed ID: 21109326
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-based double-strand oligonucleotide insertion strategy corrects metabolic abnormalities in murine glycogen storage disease type-Ia.
Samanta A; George N; Arnaoutova I; Chen HD; Mansfield BC; Hart C; Carlo T; Chou JY
J Inherit Metab Dis; 2023 Nov; 46(6):1147-1158. PubMed ID: 37467014
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
[TBL] [Abstract][Full Text] [Related]
12. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
[TBL] [Abstract][Full Text] [Related]
13. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia.
Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a.
Chou JY; Zingone A; Pan CJ
Eur J Pediatr; 2002 Oct; 161 Suppl 1():S56-61. PubMed ID: 12373573
[TBL] [Abstract][Full Text] [Related]
15. Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease.
Rajas F; Clar J; Gautier-Stein A; Mithieux G
J Inherit Metab Dis; 2015 May; 38(3):521-7. PubMed ID: 25164786
[TBL] [Abstract][Full Text] [Related]
16. Circulating exosomal microRNAs as potential biomarkers of hepatic injury and inflammation in a murine model of glycogen storage disease type 1a.
Resaz R; Cangelosi D; Morini M; Segalerba D; Mastracci L; Grillo F; Bosco MC; Bottino C; Colombo I; Eva A
Dis Model Mech; 2020 Sep; 13(9):. PubMed ID: 32620541
[TBL] [Abstract][Full Text] [Related]
17. Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9-Mediated Gene Editing.
Rutten MGS; Derks TGJ; Huijkman NCA; Bos T; Kloosterhuis NJ; van de Kolk KCWA; Wolters JC; Koster MH; Bongiovanni L; Thomas RE; de Bruin A; van de Sluis B; Oosterveer MH
Hepatology; 2021 Nov; 74(5):2491-2507. PubMed ID: 34157136
[TBL] [Abstract][Full Text] [Related]
18. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.
Luo X; Hall G; Li S; Bird A; Lavin PJ; Winn MP; Kemper AR; Brown TT; Koeberl DD
Mol Ther; 2011 Nov; 19(11):1961-70. PubMed ID: 21730973
[TBL] [Abstract][Full Text] [Related]
19. Predominance of the c.648G > T G6PC gene mutation and late complications in Korean patients with glycogen storage disease type Ia.
Kim YM; Choi JH; Lee BH; Kim GH; Kim KM; Yoo HW
Orphanet J Rare Dis; 2020 Feb; 15(1):45. PubMed ID: 32046761
[TBL] [Abstract][Full Text] [Related]
20. Generation of a human induced pluripotent stem cell line, BRCi009-A, derived from a patient with glycogen storage disease type 1a.
Katagami Y; Kondo T; Suga M; Yada Y; Imamura K; Shibukawa R; Sagara Y; Okanishi Y; Tsukita K; Hirayama K; Era T; Inoue H
Stem Cell Res; 2020 Dec; 49():102095. PubMed ID: 33291009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
